

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A
(Rule 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

(Amendment No.)

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material Under § 240.14a-12

MIND MEDICINE (MINDMED) INC.
(Name of Registrant as Specified In Its Charter)

FCM MM HOLDINGS, LLC
JAKE S. FREEMAN
CHAD BOULANGER
DR. SCOTT FREEMAN
DR. FARZIN FARZANEH
VIVEK JAIN
ALEXANDER J. WODKA

(Name of Persons(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

- No fee required
 - Fee paid previously with preliminary materials
 - Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
-

FCM MM Holdings, LLC, a Wyoming limited liability company, together with the other participants in its solicitation (collectively, "FCM"), has filed a definitive proxy statement and accompanying BLUE proxy card with the Securities and Exchange Commission to be used to solicit votes for the election of its slate of highly-qualified director nominees at the 2023 annual general meeting of shareholders of Mind Medicine (MindMed) Inc., a British Columbia corporation.

On June 1, 2023, FCM posted the following materials on Reddit:

r/MindMedInvestorsClub · Posted by u/Character_Jelly_6738 32 minutes ago

Interesting... FCM's timeline of MM-110 was not really addressed in MindMedIR's latest post 🙄🙄

1/2

Dr. Freeman Halts MM-110 Trial

2015
At INO meeting with FDA a safety directive was issued stating that MM-110 can only be administered at low doses (1-10 mg) without additional pre-clinical (animal) safety data.

2015-2019
Savant lacks funding to perform pre-clinical or clinical studies.

2019
MindMed is formed from Savant:
• Dr. Freeman becomes CMO and initiates MM-110 healthy volunteer Phase I study.
• Chief Scientific Officer, Dr. Don Dehart, had responsibility for pre-clinical safety studies, NOT Dr. Freeman.

June 15, 2020 (9:17 AM)
Dr. Freeman halted the Phase I study at 1mg due to safety concerns - humans were more sensitive to MM-110 than indicated by previous pre-clinical studies.

June 15, 2020 (12:00 PM)
Dr. Freeman is suspended from his duties as CMO (he subsequently left the Company in August 2020):
• Ms. Bridget Makes, a current board member, served as the Head of HR at the time.
• The current board should be aware of this as they performed an "independent" investigation, following FCM bringing this to the board's attention - Dr. Freeman was never interviewed or asked for his account.
• A contract research organization (who was performing the clinical trial) subsequently received a \$300,000 cancellation fee for the halting of the dosing group.

June 2020
Mr. Barrow was hired as a clinical development consultant and was appointed Chief Development Officer in January 2021.

July 2020
MM-110 patient dosing continues at 12mg dose.

January - March 2021
The MM-110 protocol is amended to dose healthy volunteers at 1200 mg per day.

December 2021
MindMed completes Phase I MM-110 study with a dosing regimen of 850 mg per day (> 30x the dose the FDA believed was safe).

May 2022
MindMed issues a press release touting the safety and tolerability of MM-110 in the Phase I study.

August 2022
MindMed announces that it met with FDA to discuss moving to Phase II trial, but FDA reiterated the need for additional pre-clinical safety studies. MindMed shuts down MM-110 program.

Source: MindMed Press Releases, Company's SEC Filings, ClinicalTrials.gov

1 Comment Share Save ...